Physician profile
Gail L Wright
NPI 1669432290
$21,234.29
in general payments reported to CMS, 2019-2025
90 companies · $2,767 in 2025
The $2,767 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,002 · 2020: $1,234 · 2021: $1,869 · 2022: $2,857 · 2023: $3,378 · 2024: $7,127 · 2025: $2,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,936 · Consulting Fee: $3,038 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,935.69 |
| Consulting Fee | $3,037.50 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,113.82 | 2019-2025 | Piqray, Kisqali |
| Janssen Biotech, INC. | $1,234.03 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Celgene Corporation | $921.59 | 2019-2025 | Reblozyl, Opdualag |
| Pfizer INC. | $884.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $869.82 | 2020-2025 | Enhertu, Imfinzi, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $865.70 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Gilead Sciences, INC. | $659.14 | 2019-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $640.75 | 2019-2025 | Keytruda, Lynparza |
| Seagen INC. | $627.83 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Genentech USA, INC. | $590.54 | 2019-2025 | Phesgo, Perjeta, Tecentriq |
| Daiichi Sankyo INC. | $517.07 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Abbvie INC. | $505.98 | 2019-2025 | Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $460.88 | 2019-2025 | Fruzaqla, Alunbrig |
| Incyte Corporation | $453.39 | 2020-2025 | Jakafi, Monjuvi |
| Genzyme Corporation | $429.45 | 2019-2025 |
Show all 85 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $423.60 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $368.56 | 2019-2025 | |
| Glaxosmithkline, LLC. | $348.03 | 2019-2025 | Ojjaara, Jemperli, Zejula |
| Exelixis INC. | $312.85 | 2019-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $274.32 | 2022-2025 | Libtayo |
| Tersera Therapeutics LLC | $273.58 | 2022-2025 | Zoladex, Xermelo, Quzyttir |
| Amgen INC. | $242.26 | 2019-2022 | |
| Beigene USA, INC. | $230.82 | 2021-2024 | Brukinsa |
| Eisai INC. | $227.04 | 2020-2025 | |
| Kite Pharma, INC. | $219.14 | 2020-2025 | Yescarta |
| Astellas Pharma US INC | $190.33 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Pharmacyclics LLC, An Abbvie Company | $187.75 | 2020-2023 | Imbruvica |
| Puma Biotechnology, INC. | $187.74 | 2019-2025 | |
| Organon LLC | $178.31 | 2023 | Ontruzant |
| Array Biopharma INC | $166.61 | 2019-2024 | Mektovi, Braftovi, Lorbrena |
| Blueprint Medicines Corporation | $157.34 | 2021-2025 | Ayvakit |
| Emd Serono, INC. | $118.49 | 2019-2025 | Bavencio |
| Mirati Therapeutics, INC. | $106.61 | 2023-2024 | Krazati |
| Octapharma USA, INC. | $89.82 | 2020 | |
| Deciphera Pharmaceuticals INC. | $89.34 | 2021-2025 | Qinlock, Tgct |
| Jazz Pharmaceuticals INC. | $87.90 | 2021-2025 | |
| Sirtex Medical INC | $87.89 | 2019 | |
| Sobi, INC | $87.09 | 2022-2025 | |
| Pharmaessentia USA Corporation | $86.50 | 2024 | Besremi |
| Legend Biotech USA INC. | $76.21 | 2024-2025 | Carvykti |
| Taiho Oncology, INC. | $71.42 | 2020-2024 | |
| Ipsen Biopharmaceuticals, INC | $68.85 | 2020-2025 | Somatuline Depot, Onivyde |
| Tempus Ai, INC | $67.98 | 2024 | Xt Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.69 | 2019-2021 | |
| Aveo Pharmaceuticals, INC. | $65.19 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $61.21 | 2019-2023 | Tavalisse, Rezlidhia |
| Beone Medicines USA, INC. | $61.02 | 2025 | Brukinsa |
| Myriad Genetic Laboratories, INC. | $60.37 | 2022-2024 | Myrisk |
| G1 Therapeutics, INC. | $60.12 | 2022-2023 | Cosela |
| Alexion Pharmaceuticals, INC. | $55.71 | 2019-2025 | Ultomiris |
| Springworks Therapeutics, INC. | $53.35 | 2024 | Ogsiveo |
| Pharmacosmos Therapeutics INC. | $52.08 | 2023-2024 | Monoferric, Cosela |
| Medtronic, INC. | $50.59 | 2022 | |
| Dova Pharmaceuticals | $50.51 | 2020-2021 | |
| Morphosys, US INC. | $49.86 | 2021-2023 | Monjuvi |
| Epizyme, INC. | $48.16 | 2021-2022 | |
| Adc Therapeutics America, INC. | $47.62 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $45.98 | 2020-2022 | |
| Myovant Sciences INC. | $44.32 | 2021 | |
| Geron Corporation | $40.96 | 2025 | Rytelo |
| Fennec Pharmaceuticals, INC. | $39.47 | 2024 | Pedmark |
| Janssen Pharmaceuticals, INC | $38.70 | 2020-2023 | Xarelto |
| Servier Pharmaceuticals LLC | $37.13 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $36.27 | 2023 | Empaveli |
| Csl Behring | $32.77 | 2019-2021 | |
| Tesaro, INC. | $31.89 | 2019 | |
| Acrotech Biopharma INC. | $29.88 | 2022-2024 | Ryzneuta |
| Adaptive Biotechnologies Corporation | $23.77 | 2024 | Clonoseq |
| Foundation Medicine, INC. | $22.41 | 2023 | |
| Immunogen, INC. | $22.36 | 2023 | Elahere |
| Syndax Pharmaceuticals, INC. | $20.54 | 2025 | |
| Stemline Therapeutics INC. | $18.02 | 2023 | Orserdu |
| Ethicon US, LLC | $17.81 | 2019 | |
| Tg Therapeutics, INC. | $16.67 | 2021 | |
| Cti Biopharma Corp. | $16.12 | 2023 | Vonjo |
| Shire North American Group INC | $15.86 | 2019 | |
| Sanofi Pasteur INC. | $15.86 | 2019 | |
| Novocure INC. | $15.59 | 2019 | |
| Dendreon Pharmaceuticals LLC | $14.49 | 2023 | Provenge |
| Ge Healthcare | $14.36 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $14.09 | 2019 | |
| Kyowa Kirin, INC. | $13.12 | 2023 | Poteligeo |
| Clovis Oncology, INC. | $8.19 | 2019 | |
| Adma Biomanufacturing LLC | $4.04 | 2022 | |
| Veracyte, INC. | $0.55 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gail Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.